Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity
暂无分享,去创建一个
Hua Yu | Tianhong Wang | Maciej Kujawski | Shari Pilon-Thomas | Hua Yu | R. Jove | Sheng Wei | M. Kortylewski | D. Pardoll | G. Niu | J. Mulé | Shumin M. Zhang | W. Kerr | Tianhong Wang | Richard Jove | Drew Pardoll | Marcin Kortylewski | S. Pilon-Thomas | Sheng Wei | Shumin Zhang | Guilian Niu | Heidi Kay | James Mulé | William G Kerr | M. Kujawski | Heidi Kay
[1] P. Musiani,et al. Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. , 2004, Cytokine.
[2] J. Blattman,et al. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. , 2003, Cancer Cell.
[3] Hua Yu,et al. A critical role for Stat3 signaling in immune tolerance. , 2003, Immunity.
[4] Valeria Poli,et al. Mutational switch of an IL-6 response to an interferon-gamma-like response. , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[5] Antonio Lanzavecchia,et al. Regulation of T Cell Immunity by Dendritic Cells , 2001, Cell.
[6] D. Pardoll,et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. , 1991, Science.
[7] P. Allavena,et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.
[8] D. Pardoll,et al. Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.
[9] J. Darnell,et al. The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.
[10] I. M. Neiman,et al. [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.
[11] A. Houghton,et al. Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells , 2004, The Journal of experimental medicine.
[12] S. Akira,et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. , 1999, Immunity.
[13] Jin Hong Liu,et al. Control of Lytic Function by Mitogen-activated Protein Kinase/Extracellular Regulatory Kinase 2 (ERK2) in a Human Natural Killer Cell Line: Identification of Perforin and Granzyme B Mobilization by Functional ERK2 , 1998, The Journal of experimental medicine.
[14] D. Carbone,et al. Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] M. Mizumoto,et al. Spleen‐derived dendritic cells engineered to enhance interleukin‐12 production elicit therapeutic antitumor immune responses , 2000, International journal of cancer.
[16] M. Nishimura,et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. , 2002, Immunity.
[17] Hua Yu,et al. The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.
[18] M. Smyth,et al. Close encounters of different kinds: Dendritic cells and NK cells take centre stage , 2005, Nature Reviews Immunology.
[19] D. Levy,et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. , 2001, Molecular cell.
[20] J. Turkson,et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. , 2004, Molecular cancer therapeutics.
[21] Youjin Lee,et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors , 2005, The Journal of experimental medicine.
[22] Michel C. Nussenzweig,et al. Dendritic Cells Induce Peripheral T Cell Unresponsiveness under Steady State Conditions in Vivo , 2001, The Journal of experimental medicine.
[23] G. Dranoff,et al. Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.
[24] J. Trapani,et al. Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells , 2000, The Journal of experimental medicine.
[25] Hua Yu,et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.
[26] R. Jove,et al. Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.
[27] E. Fikrig,et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: A critical role of STAT3 in innate immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] D. Levy,et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target , 2005, Nature Medicine.
[29] A. Cuenca,et al. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. , 2001, Blood.
[30] H. Maguire,et al. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. , 1999, Cancer research.
[31] G. Trinchieri,et al. Plasmacytoid dendritic cells in immunity , 2004, Nature Immunology.
[32] Christophe Caux,et al. Tumour escape from immune surveillance through dendritic cell inactivation. , 2002, Seminars in cancer biology.
[33] R. DePinho,et al. STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation. , 2002, Immunity.
[34] R. Flavell,et al. STAT3 is required for Flt3L-dependent dendritic cell differentiation. , 2003, Immunity.
[35] S. Akira,et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[36] G. Trinchieri,et al. Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor Antibody , 2002, The Journal of experimental medicine.
[37] Valeria Poli,et al. Mutational switch of an IL-6 response to an interferon-γ-like response , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[39] C. Desponts,et al. Influence of SHIP on the NK Repertoire and Allogeneic Bone Marrow Transplantation , 2002, Science.
[40] N. Shastri,et al. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages , 2000, Nature Immunology.
[41] G. Trinchieri,et al. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. , 2005, Cancer research.
[42] M. Jaroszeski,et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.
[43] M. Colombo,et al. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. , 2003, Blood.
[44] M. Baccarani,et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. , 2002, Blood.
[45] M Aguet,et al. Inducible gene targeting in mice , 1995, Science.
[46] J. Darnell,et al. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] H. Schreiber,et al. Bystander elimination of antigen loss variants in established tumors , 2004, Nature Medicine.